Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.25 Million EUR | -9.74% |
| 2022 | 6.93 Million EUR | -9.53% |
| 2021 | 7.66 Million EUR | 11.55% |
| 2020 | 6.86 Million EUR | 87.55% |
| 2019 | 3.66 Million EUR | 52.58% |
| 2018 | 2.4 Million EUR | 218.54% |
| 2017 | 753.59 Thousand EUR | 115.08% |
| 2016 | 350.37 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 5.98 Million EUR | -1.6% |
| 2024 Q1 | 6.07 Million EUR | -2.85% |
| 2023 Q2 | 6.51 Million EUR | -3.81% |
| 2023 FY | 6.25 Million EUR | -9.74% |
| 2023 Q4 | 6.25 Million EUR | -1.18% |
| 2023 Q3 | 6.33 Million EUR | -2.84% |
| 2023 Q1 | 6.77 Million EUR | -2.28% |
| 2022 Q1 | 7.45 Million EUR | -2.69% |
| 2022 Q4 | 6.93 Million EUR | -2.49% |
| 2022 Q3 | 7.11 Million EUR | -2.28% |
| 2022 Q2 | 7.27 Million EUR | -2.43% |
| 2022 FY | 6.93 Million EUR | -9.53% |
| 2021 FY | 7.66 Million EUR | 11.55% |
| 2021 Q4 | 7.66 Million EUR | 1.04% |
| 2021 Q3 | 7.58 Million EUR | 36.5% |
| 2021 Q2 | 5.55 Million EUR | -16.89% |
| 2021 Q1 | 6.68 Million EUR | -2.68% |
| 2020 FY | 6.86 Million EUR | 87.55% |
| 2020 Q2 | 5.4 Million EUR | 0.09% |
| 2020 Q4 | 6.86 Million EUR | 0.62% |
| 2020 Q3 | 6.82 Million EUR | 26.31% |
| 2020 Q1 | 5.4 Million EUR | 47.43% |
| 2019 Q4 | 3.66 Million EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 3.66 Million EUR | 52.58% |
| 2018 FY | 2.4 Million EUR | 218.54% |
| 2017 FY | 753.59 Thousand EUR | 115.08% |
| 2016 FY | 350.37 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biohit Oyj | 700 Thousand EUR | -793.92% |
| Herantis Pharma Oyj | 34.82 Thousand EUR | -17870.314% |